Penny fletcher’s testimony at fda public hearing on benlysta

Penny fletcher\’s testimony at fda public hearing on benlysta

On November 16, 2010 the FDA held hearings to discuss BENLYSTA, sponsored by Human Genome Sciences, for the proposed indication of reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Click bit.ly to access transcript of testimony from Penny C. Fletcher, President & CEO of the Lupus Foundation of America, DC-MD-VA Chapter….



Penny fletcher\’s testimony at fda public hearing on benlysta